These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 19962780)

  • 1. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
    Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Rad51 down-regulation and extracellular signal-regulated kinases 1 and 2 inactivation in emodin and mitomycin C-induced synergistic cytotoxicity in human non-small-cell lung cancer cells.
    Su YJ; Tsai MS; Kuo YH; Chiu YF; Cheng CM; Lin ST; Lin YW
    Mol Pharmacol; 2010 Apr; 77(4):633-43. PubMed ID: 20042515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of Rad51, ERCC1, and thymidine phosphorylase by emodin result in synergistic cytotoxic effect in combination with capecitabine.
    Ko JC; Tsai MS; Kuo YH; Chiu YF; Weng SH; Su YC; Lin YW
    Biochem Pharmacol; 2011 Mar; 81(5):680-90. PubMed ID: 21168393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells.
    Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Lin YW
    Biochem Pharmacol; 2010 Feb; 79(4):655-64. PubMed ID: 19799875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.
    Chen RS; Jhan JY; Su YJ; Lee WT; Cheng CM; Ciou SC; Lin ST; Chuang SM; Ko JC; Lin YW
    Exp Cell Res; 2009 Sep; 315(15):2658-72. PubMed ID: 19505457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1).
    Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
    Mol Pharmacol; 2011 Jul; 80(1):136-46. PubMed ID: 21493726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Up-regulation of extracellular signal-regulated kinase 1/2-dependent thymidylate synthase and thymidine phosphorylase contributes to cisplatin resistance in human non-small-cell lung cancer cells.
    Ko JC; Tsai MS; Chiu YF; Weng SH; Kuo YH; Lin YW
    J Pharmacol Exp Ther; 2011 Jul; 338(1):184-94. PubMed ID: 21444628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells.
    Ko JC; Tsai MS; Weng SH; Kuo YH; Chiu YF; Lin YW
    Toxicol Appl Pharmacol; 2011 Sep; 255(3):327-38. PubMed ID: 21810436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
    Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP; Liu BR; Shi MQ; Liu XZ; Hu WJ; Zou ZY; Wei J
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):33-7. PubMed ID: 19538866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA; Mountzios G; Soria JC
    Curr Opin Pulm Med; 2007 Jul; 13(4):284-9. PubMed ID: 17534174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells.
    Ko JC; Chen HJ; Huang YC; Tseng SC; Weng SH; Wo TY; Huang YJ; Chiu HC; Tsai MS; Chiou RY; Lin YW
    Regul Toxicol Pharmacol; 2012 Dec; 64(3):415-24. PubMed ID: 23069143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roles of MKK1/2-ERK1/2 and phosphoinositide 3-kinase-AKT signaling pathways in erlotinib-induced Rad51 suppression and cytotoxicity in human non-small cell lung cancer cells.
    Ko JC; Ciou SC; Jhan JY; Cheng CM; Su YJ; Chuang SM; Lin ST; Chang CC; Lin YW
    Mol Cancer Res; 2009 Aug; 7(8):1378-89. PubMed ID: 19671683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
    Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E; Rosell R
    Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC.
    Cai Y; Yan X; Zhang G; Zhao W; Jiao S
    Oncotarget; 2015 Aug; 6(22):18997-9005. PubMed ID: 25944617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of thymidine phosphorylase expression by using an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells.
    Weng SH; Tseng SC; Huang YC; Chen HJ; Lin YW
    Biochem Pharmacol; 2012 Jul; 84(1):126-36. PubMed ID: 22480737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
    Jiao JW; Wen F
    Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.